We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Computer System Launched To Manage Blood Screening Data

By LabMedica International staff writers
Posted on 21 Oct 2008
A computer system was launched that improves laboratory efficiency by managing test data when screening donated blood for hepatitis and retroviruses.

The new system will enable laboratories to track and trend quality control and performance of blood-screening assays and will provide laboratories with robust data capabilities through expanded archival features. More...
It also will help blood-screening laboratories manage retesting of samples, produce reports, and generate statistical charts.

Called the Abbott Prism Director, the new system was launched by Abbott (Abbott Park, IL, USA) at the American Association of Blood Banks annual meeting on October 7, 2008, in Montreal, Canada. The Abbott Prism is an automated immunoassay analyzer designed to perform in vitro diagnostic donor screening for hepatitis and retroviruses. The analyzer is used by blood, plasma, organ, and tissue centers in more than 30 countries to screen more than 40 million donations each year.

"The worldwide launch of the Abbott Prism Director brings an important new product to our expanding portfolio of blood-screening systems and assays and demonstrates our continued commitment to blood-screening laboratories and the overall safety of the blood supply,” said James Stewart, Ph.D., director of research and development, Abbott Diagnostics. "For testing facilities that use multiple or single Abbott Prism instruments, the Abbott Prism Director offers data management functionality that can significantly enhance laboratory operations.”

Abbott is a global leader in in vitro diagnostics and provides a broad range of instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices, and clinics. The company's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility.

Related Links:
Abbott


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.